Novo Nordisk discloses IT security incident but gives no details
Novo Nordisk has confirmed an IT security incident in a June 11 press release, but has not said what was affected or whether patient data or medicine supplies are involved.
Novo Nordisk disclosed an information-technology security incident at the company in a press release dated June 11, 2026, according to the company's news archive [1]. The entry carries the title "Novo Nordisk A/S: IT Security incident at Novo Nordisk" and provides no further description of what happened [1].
The archive lists the item as a press release, which Novo Nordisk says is intended for the media; a separate category, company announcements, is intended for investors [1]. What systems were involved, whether any data was accessed or taken, and whether manufacturing, shipping or prescription records were affected have not been disclosed in that listing [1]. It is also not yet known how many people, if any, were affected, or whether the company expects any effect on the supply of its medicines [1].
The disclosure came during a period when Novo Nordisk's financial results have moved in different directions depending on which figures are used. In its half-year report published Aug. 4, 2026, the company reported second-quarter adjusted operating profit of DKK 33,389 million, up 11% at constant exchange rates, while reported operating profit fell 16% at constant exchange rates [2]. Reported net profit for the quarter was DKK 20,989 million, down 21% [2]. The quarter included DKK 6.3 billion in non-cash impairment charges tied to pipeline assets, of which DKK 4.0 billion related to monlunabant [2]. Novo Nordisk said it now expects adjusted sales growth of 0% to -6% at constant exchange rates for 2026 and adjusted operating profit growth of 0% to -6% [2].
Semaglutide products remain the center of the company's results. Novo Nordisk reported more than 265,000 US weekly prescriptions for the week ending July 17 for the Wegovy pill, which has reached more than 5 million prescriptions since launch [2]. Total Wegovy prescriptions for that week were around 575,000 [2]. Second-quarter adjusted sales were DKK 31,375 million for Ozempic, DKK 19,484 million for Wegovy injectable, DKK 3,218 million for Wegovy pill and DKK 5,228 million for Rybelsus [2].
Why it matters for patients
Novo Nordisk makes the semaglutide medicines sold in the US as Ozempic, Wegovy and Rybelsus [2], so a security incident at the company raises two practical questions for people who take them: whether their personal information was involved, and whether supplies could be interrupted. Neither question has been answered publicly. The company has not described the scope of the incident, the types of data that may have been affected, or any effect on manufacturing or supply [1].
That leaves patients unable to judge from the company's own material whether the event touches them. Depending on what was affected, notification could come from the drugmaker, a health plan or a pharmacy, but Novo Nordisk has not described any notification process [1]. The company also has not said whether the incident is contained or ongoing, or when it was first detected [1].
What happens next
The June 11 release is the only item in Novo Nordisk's news archive about the incident. The titles of later entries, including the Aug. 4 half-year results and a Sept. 14 corporate announcement, do not reference it, and the half-year report's highlighted items do not mention it [1][2]. Novo Nordisk has not said whether it will publish further information, and no timeline for an update has been reported [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.